{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:00:16Z","timestamp":1792425616129,"version":"4.5.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.eprac.2021.12.017","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T20:33:23Z","timestamp":1642019603000},"page":"321-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Personalized Medical Treatment of Patients With Acromegaly: A\u00a0Review"],"prefix":"10.1016","volume":"28","author":[{"given":"Dawn Shao Ting","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.eprac.2021.12.017_bib1","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J\u00a0Clin Invest"},{"issue":"14","key":"10.1016\/j.eprac.2021.12.017_bib2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A\u00a0meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume":"159","author":"Holdaway","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jc.2003-031199","article-title":"Factors influencing mortality in acromegaly","volume":"89","author":"Holdaway","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.017_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1530\/ERC-16-0106","article-title":"Mortality in acromegaly: a 20-year follow-up study","volume":"23","author":"Ritvonen","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11102-011-0308-1","article-title":"Excess mortality for patients with residual disease following resection of pituitary adenomas","volume":"14","author":"Sughrue","year":"2011","journal-title":"Pituitary"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.017_bib8","first-page":"3419","article-title":"Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly","volume":"83","author":"Swearingen","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"issue":"11","key":"10.1016\/j.eprac.2021.12.017_bib10","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2021.12.017_bib11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A\u00a0consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A\u00a0Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"9","key":"10.1016\/j.eprac.2021.12.017_bib13","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1210\/jc.2011-0554","article-title":"Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome","volume":"96","author":"Jane Jr JA","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2021.12.017_bib14","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1210\/jc.2013-1036","article-title":"Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission","volume":"98","author":"Starke","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.017_bib15","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11102-020-01063-x","article-title":"Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review","volume":"23","author":"Agrawal","year":"2020","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/jc.2014-2468","article-title":"A\u00a0structural and functional acromegaly classification","volume":"100","author":"Cuevas-Ramos","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.017_bib17","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11102-015-0693-y","article-title":"Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study","volume":"19","author":"Caron","year":"2016","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.017_bib19","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.017_bib20","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11102-010-0282-z","article-title":"Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review","volume":"14","author":"Fleseriu","year":"2011","journal-title":"Pituitary"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.017_bib22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s12325-011-0062-9","article-title":"Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors","volume":"28","author":"Ludlam","year":"2011","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1210\/jc.2005-1208","article-title":"Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly","volume":"91","author":"Colao","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.017_bib24","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1365-2265.2007.03139.x","article-title":"Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide","volume":"68","author":"Karavitaki","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.017_bib25","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s11102-017-0832-8","article-title":"Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly","volume":"20","author":"Fahlbusch","year":"2017","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to somatostatin analogs in acromegaly","volume":"32","author":"Colao","year":"2011","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.017_bib27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","author":"Gadelha","year":"2013","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib28","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-17-1006","article-title":"Management of endocrine disease: personalized medicine in the treatment of acromegaly","volume":"178","author":"Kasuki","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib29","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1210\/clinem\/dgz054","article-title":"Effects of pegvisomant and pasireotide LAR on vertebral fractures in acromegaly resistant to first-generation SRLs","volume":"105","author":"Chiloiro","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib30","first-page":"20","article-title":"Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology","volume":"33","author":"Yamada","year":"1993","journal-title":"Neurosurgery"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.017_bib31","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","article-title":"Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly","volume":"76","author":"Fougner","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-13-0349","article-title":"Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern","volume":"169","author":"Kasuki","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.017_bib34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-12-0864","article-title":"Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas","volume":"168","author":"Larkin","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1507\/endocrj.EJ11-0177","article-title":"Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas","volume":"59","author":"Kato","year":"2012","journal-title":"Endocr J"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib36","doi-asserted-by":"crossref","first-page":"R223","DOI":"10.1530\/JME-14-0011","article-title":"Somatostatin receptor ligands and resistance to treatment in pituitary adenomas","volume":"52","author":"Cuevas-Ramos","year":"2014","journal-title":"J\u00a0Mol Endocrinol"},{"issue":"11","key":"10.1016\/j.eprac.2021.12.017_bib37","doi-asserted-by":"crossref","first-page":"E1730","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide","volume":"98","author":"Casar-Borota","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib38","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in\u00a0vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.eprac.2021.12.017_bib40","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1210\/jc.2010-0573","article-title":"Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.017_bib42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11102-018-0877-3","article-title":"Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas","volume":"21","author":"Dogansen","year":"2018","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","article-title":"Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly","volume":"52","author":"Heck","year":"2016","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.017_bib44","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00330-018-5876-2","article-title":"Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI","volume":"29","author":"Kocak","year":"2019","journal-title":"Eur Radiol"},{"issue":"9","key":"10.1016\/j.eprac.2021.12.017_bib45","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1210\/clinem\/dgaa387","article-title":"Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2021.12.017_bib46","first-page":"4712","article-title":"Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation","volume":"85","author":"Leung","year":"2000","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/eje.1.01968","article-title":"Predictors and rates of treatment-resistant tumor growth in acromegaly","volume":"153","author":"Besser","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib48","doi-asserted-by":"crossref","first-page":"L25","DOI":"10.1530\/ERC-12-0020","article-title":"AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression","volume":"19","author":"Kasuki","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"10.1016\/j.eprac.2021.12.017_bib49","doi-asserted-by":"crossref","first-page":"E1411","DOI":"10.1210\/jc.2012-1111","article-title":"Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway","volume":"97","author":"Chahal","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/EJE-12-0457","article-title":"Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues","volume":"168","author":"Oriola","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2021.12.017_bib51","doi-asserted-by":"crossref","first-page":"E2789","DOI":"10.1210\/jc.2014-2094","article-title":"Frequency of AIP gene mutations in young patients with acromegaly: a registry-based study","volume":"99","author":"Sch\u00f6fl","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2021.12.017_bib52","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.017_bib53","doi-asserted-by":"crossref","first-page":"668","DOI":"10.4158\/EP14575.DSCR","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: management of acromegaly patients: what is the role of pre-operative medical therapy?","volume":"21","author":"Fleseriu","year":"2015","journal-title":"Endocr Pract"},{"issue":"8","key":"10.1016\/j.eprac.2021.12.017_bib54","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1210\/jc.2008-0315","article-title":"Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial","volume":"93","author":"Carlsen","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib55","first-page":"517","article-title":"Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma","volume":"40","author":"Li","year":"2012","journal-title":"J\u00a0Int Med Res"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.017_bib56","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1530\/EJE-09-0908","article-title":"Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial","volume":"162","author":"Mao","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2021.12.017_bib57","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1507\/endocrj.K10E-203","article-title":"Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study","volume":"57","author":"Shen","year":"2010","journal-title":"Endocr J"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib58","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12020-015-0853-x","article-title":"Pros and cons in endocrine practice: pre-surgical treatment with somatostatin analogues in acromegaly","volume":"52","author":"Losa","year":"2016","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib59","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-14-0249","article-title":"Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial","volume":"171","author":"Fougner","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.017_bib60","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11102-018-0916-0","article-title":"Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly","volume":"21","author":"Albarel","year":"2018","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.017_bib61","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00701-005-0511-9","article-title":"Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study","volume":"147","author":"Plockinger","year":"2005","journal-title":"Acta Neurochir (Wien)"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib62","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12902-017-0205-3","article-title":"Prolonged preoperative treatment of acromegaly with somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): a retrospective cohort study conducted at a single center","volume":"17","author":"Duan","year":"2017","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.eprac.2021.12.017_bib63","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clineuro.2018.02.006","article-title":"Presurgical treatment with somatostatin analogues in growth hormone-secreting pituitary adenomas: a long-term single-center experience","volume":"167","author":"Lv","year":"2018","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib64","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s11102-015-0677-y","article-title":"The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.017_bib65","doi-asserted-by":"crossref","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib66","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1210\/jc.2004-1093","article-title":"Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly","volume":"90","author":"Bevan","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.017_bib67","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib68","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11102-019-01020-3","article-title":"Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study","volume":"23","author":"Petersenn","year":"2020","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.017_bib69","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.017_bib70","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.017_bib71","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s11102-021-01163-2","article-title":"Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results","volume":"24","author":"Labadzhyan","year":"2021","journal-title":"Pituitary"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2021.12.017_bib72","doi-asserted-by":"crossref","first-page":"A517","DOI":"10.1210\/jendso\/bvab048.1056","article-title":"A\u00a0Phase 3 Large International Noninferiority Trial (MPOWERED): assessing maintenance of response to oral octreotide capsules in comparison to injectable somatostatin receptor ligands","volume":"5","author":"Fleseriu","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.eprac.2021.12.017_bib73","doi-asserted-by":"crossref","unstructured":"Fleseriu M, Dreval A, Bondar I, et\u00a0al. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Preprint. Posted online December 22, 2021. Lancet Diabetes Endocrinol. https:\/\/doi.org\/10.1016\/S2213-8587(21)00296-5","DOI":"10.1016\/S2213-8587(21)00296-5"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib74","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","article-title":"Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider","volume":"23","author":"Geer","year":"2020","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib75","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2021.12.017_bib76","doi-asserted-by":"crossref","first-page":"A649","DOI":"10.1210\/jendso\/bvab048.1324","article-title":"The pharmacological burden of comorbidities in acromegaly","volume":"5","author":"Fleseriu","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib77","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/EJE-16-0697","article-title":"Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis","volume":"176","author":"Tritos","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"9295","key":"10.1016\/j.eprac.2021.12.017_bib78","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib79","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4158\/EP14330.OR","article-title":"Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY","volume":"21","author":"Freda","year":"2015","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib80","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12020-018-1729-7","article-title":"Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies","volume":"63","author":"Leonart","year":"2019","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib81","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/eje.1.02312","article-title":"Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study","volume":"156","author":"Schreiber","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.017_bib82","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4158\/EP-2019-0528","article-title":"Comparative efficacy of medical treatment for acromegaly: a systematic review and network meta-analysis of integrated randomized trials and observational studies","volume":"26","author":"Qiao","year":"2020","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.017_bib83","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY","volume":"185","author":"Fleseriu","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.017_bib84","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1530\/EJE-19-0794","article-title":"All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis","volume":"182","author":"Tritos","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.017_bib85","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40618-017-0773-0","article-title":"How to improve effectiveness of pegvisomant treatment in acromegalic patients","volume":"41","author":"Ragonese","year":"2018","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.017_bib86","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1530\/EJE-16-0956","article-title":"A\u00a0multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues","volume":"176","author":"Franck","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.017_bib87","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s11102-015-0673-2","article-title":"Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort","volume":"18","author":"Sievers","year":"2015","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib88","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s12020-018-1792-0","article-title":"Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy","volume":"63","author":"Brue","year":"2019","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib89","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12020-018-1797-8","article-title":"Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicetre cohort, and review of the literature","volume":"63","author":"Briet","year":"2019","journal-title":"Endocrine"},{"issue":"8","key":"10.1016\/j.eprac.2021.12.017_bib90","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1517\/14740338.2015.1059817","article-title":"Adverse events associated with somatostatin analogs in acromegaly","volume":"14","author":"Grasso","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.017_bib91","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","article-title":"Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies","volume":"94","author":"Mazziotti","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.017_bib92","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1210\/jc.2017-02566","article-title":"Somatostatin analogs and glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies","volume":"103","author":"Cozzolino","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.017_bib93","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1210\/jc.2005-0331","article-title":"Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant","volume":"90","author":"Barkan","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.017_bib94","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1530\/eje.0.1490521","article-title":"Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant","volume":"149","author":"Drake","year":"2003","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2021.12.017_bib95","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2018-02281","article-title":"Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies","volume":"104","author":"Feola","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2021.12.017_bib96","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1210\/jc.2008-2086","article-title":"Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly","volume":"94","author":"Higham","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib97","doi-asserted-by":"crossref","first-page":"bvab004","DOI":"10.1210\/jendso\/bvab004","article-title":"Body composition changes with long-term pegvisomant therapy of acromegaly","volume":"5","author":"Kuker","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-016-0096-8","article-title":"Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, phase III study","volume":"16","author":"Bronstein","year":"2016","journal-title":"BMC Endocr Disord"},{"issue":"11","key":"10.1016\/j.eprac.2021.12.017_bib99","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.017_bib100","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1210\/jc.2018-01979","article-title":"How to position pasireotide LAR treatment in acromegaly","volume":"104","author":"Coopmans","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2021.12.017_bib101","doi-asserted-by":"crossref","first-page":"648411","DOI":"10.3389\/fendo.2021.648411","article-title":"Pasireotide in the personalized treatment of acromegaly","volume":"12","author":"Puig-Domingo","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib102","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1210\/jc.2018-01524","article-title":"Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression","volume":"104","author":"Muhammad","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1-3","key":"10.1016\/j.eprac.2021.12.017_bib103","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejphar.2010.07.005","article-title":"Absence of somatostatin SST(2) receptor internalization in\u00a0vivo after intravenous SOM230 application in the AR42J animal tumor model","volume":"644","author":"Waser","year":"2010","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib104","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.017_bib105","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1530\/EC-19-0332","article-title":"Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study","volume":"8","author":"Lasolle","year":"2019","journal-title":"Endocr Connect"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib106","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-20-0767","article-title":"Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response","volume":"184","author":"Chiloiro","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib107","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE study)","volume":"103","author":"Muhammad","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.017_bib108","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.017_bib109","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/EC-19-0004","article-title":"AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients","volume":"8","author":"Daly","year":"2019","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12020-016-1182-4","article-title":"Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study","volume":"55","author":"Fleseriu","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.eprac.2021.12.017_bib111","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fendo.2019.00931","article-title":"Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs","volume":"10","author":"Gadelha","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.017_bib112","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-18-0353","article-title":"Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study","volume":"179","author":"Muhammad","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2021.12.017_bib113","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1530\/EC-20-0361","article-title":"Risk factors and management of pasireotide-associated hyperglycemia in acromegaly","volume":"9","author":"Gadelha","year":"2020","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib114","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11102-016-0737-y","article-title":"The role of combination medical therapy in the treatment of acromegaly","volume":"20","author":"Lim","year":"2017","journal-title":"Pituitary"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.017_bib115","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1210\/jc.2014-2032","article-title":"Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly","volume":"99","author":"Neggers","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.017_bib116","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2009.03620.x","article-title":"A\u00a0randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly","volume":"71","author":"Trainer","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib117","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-10-0867","article-title":"Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone","volume":"164","author":"van der Lely","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"9471","key":"10.1016\/j.eprac.2021.12.017_bib118","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(05)63011-5","article-title":"Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly","volume":"365","author":"Feenstra","year":"2005","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.eprac.2021.12.017_bib119","doi-asserted-by":"crossref","first-page":"dgaa444","DOI":"10.1210\/clinem\/dgaa444","article-title":"Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial","volume":"105","author":"Bonert","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.017_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-9966-32-40","article-title":"Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes","volume":"32","author":"Bianchi","year":"2013","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.017_bib121","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/cen.12314","article-title":"Headache and pituitary disease: a systematic review","volume":"79","author":"Kreitschmann-Andermahr","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.017_bib122","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1210\/jc.2008-0669","article-title":"Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant","volume":"93","author":"Neggers","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2021.12.017_bib123","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1210\/jc.2019-00825","article-title":"Pasireotide and pegvisomant combination treatment in acromegaly resistant to second-line therapies: a longitudinal study","volume":"104","author":"Chiloiro","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib124","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12020-021-02711-3","article-title":"Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus pegvisomant","volume":"73","author":"Chiloiro","year":"2021","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.017_bib125","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/cen.13595","article-title":"Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands","volume":"88","author":"Kasuki","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib126","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000317314","article-title":"Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling IGF-I levels in acromegaly","volume":"92","author":"Mattar","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"8","key":"10.1016\/j.eprac.2021.12.017_bib127","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.endonu.2016.05.010","article-title":"Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: the ACROCOMB study","volume":"63","author":"Puig-Domingo","year":"2016","journal-title":"Endocrinol Nutr"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.017_bib128","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1507\/endocrj.EJ12-0272","article-title":"Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature","volume":"60","author":"Suda","year":"2012","journal-title":"Endocr J"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib129","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11102-010-0272-1","article-title":"Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR","volume":"14","author":"Vilar","year":"2011","journal-title":"Pituitary"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2021.12.017_bib130","doi-asserted-by":"crossref","first-page":"A518","DOI":"10.1210\/jendso\/bvab048.1058","article-title":"Addition of cabergoline to oral octreotide capsules may improve biochemical control in patients with acromegaly who are inadequately controlled with monotherapy","volume":"5","author":"Fleseriu","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.017_bib131","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1210\/jc.2011-2603","article-title":"Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial","volume":"97","author":"Higham","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib132","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1365-2265.2002.01597.x","article-title":"Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties","volume":"57","author":"Webb","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.017_bib133","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11102-020-01038-y","article-title":"An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies","volume":"23","author":"Fleseriu","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.eprac.2021.12.017_bib134","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fendo.2017.00040","article-title":"Predictors of quality of life in acromegaly: no consensus on biochemical parameters","volume":"8","author":"Geraedts","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.017_bib135","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1210\/clinem\/dgaa868","article-title":"Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis","volume":"106","author":"Broersen","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.017_bib136","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s11102-018-0908-0","article-title":"Cost-effectiveness of acromegaly treatments: a systematic review","volume":"21","author":"Leonart","year":"2018","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.017_bib137","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11102-011-0310-7","article-title":"Clinical, quality of life, and economic value of acromegaly disease control","volume":"14","author":"Ben-Shlomo","year":"2011","journal-title":"Pituitary"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:12:53Z","timestamp":1761516773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":137,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1530891X22000040"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2021.12.017","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized Medical Treatment of Patients With Acromegaly: A\u00a0Review","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2021.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}